The FDA decision on Amylyx Pharmaceuticals Inc.’s (AMLX) AMX0035, proposed for the treatment of amyotrophic lateral sclerosis is expected on June 29, 2022.An FDA panel that scrutinized AMX0035, in March of this year, had voted 4 "Yes" and 6 "No" to the question "Do the data from the single randomized, controlled trial and the open-label extension study establish a conclusion that AMX0035 is effective in the treatment of patients with amyotrophic lateral sclerosis?"The FDA usually follows the recommendations of its advisory panels, although it is not required to do so.Mitsubishi Tanabe’s Radicava; Sanofi-Aventis’ Rilutek; ITF Pharma’s Tiglutik; Aquestive Therapeutics’ Exservan; and Avanir Pharma’s Nuedexta are some of the drugs approved by the FDA to treat amyotrophic lateral sclerosis and its symptoms.AMLX closed Thursday’s (May 26, 2022) trading at $7.84.